Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of TD-4208 in Healthy Male Subjects
NCT02772159Phase 1Completed
- Sponsor
- Mylan
- Start
- Jun 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of revefenacin in chronic obstructive pulmonary disease (COPD), sponsored by Mylan. Primary endpoints: [14C] total radioactivity in urine at 336 hours and [14C] total radioactivity in feces at 336 hours. Started Jun 2015; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02772159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772159.